Gao Song, Wang Jiaqian, Zhu Zhongzheng, Fang Juemin, Zhao Yu, Liu Zhuqing, Qin Huanlong, Wei Yuquan, Xu Heng, Dan Xu, Yang Li, Xu Qing
Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Tongji University Cancer Center, Shanghai, 200072, China.
Immunotherapy. 2023 Feb;15(2):57-69. doi: 10.2217/imt-2021-0339. Epub 2023 Jan 18.
Although significant progress has been made in immune checkpoint inhibitor (ICI) treatment of advanced squamous cell carcinoma (SqCC), most patients still experience acquired drug resistance. We used a dendritic cell-based neoantigen vaccine combined with ICIs to treat advanced SqCC in a PD-1 blockade-resistant patient. The follow-up of this patient after 12 months revealed significant tumor regression. We also identified a new ICI-resistant mutation that could become a potential universal neoantigen target for tumor vaccines. Individualized management of advanced SqCC through a combined neoantigen vaccine and ICI administration could yield beneficial clinical outcomes. Vaccines targeting anti-PD-1-resistant mutations might be of particular benefit to a specific group of solid tumor patients.
尽管免疫检查点抑制剂（ICI）治疗晚期鳞状细胞癌（SqCC）已取得显著进展，但大多数患者仍会出现获得性耐药。我们使用基于树突状细胞的新抗原疫苗联合ICI治疗一名对PD-1阻断耐药的晚期SqCC患者。该患者随访12个月后显示肿瘤显著消退。我们还鉴定出一种新的ICI耐药突变，其可能成为肿瘤疫苗潜在的通用新抗原靶点。通过联合新抗原疫苗和ICI给药对晚期SqCC进行个体化管理可能会产生有益的临床结果。针对抗PD-1耐药突变的疫苗可能对特定组别的实体瘤患者特别有益。
